Summan Antibodies are thought to bring about tumour cell lvsis by antibods-dependent cell-mediated cvtotoxicitv (ADCC). but the exact mechanism is not well elucidated. Monocvtes are known to be important mediators of anti-tumour ADCC and are also known to secrete the cvtokines tumour necrosis factor alpha (TNF-m) and interleukin lp (IL-1p). both of which have been shown to bnrng about tumour cell lysis. We examined the release of these cvtokines during ADCC and attempted to elucidate which components of the ADCC reaction were necessary for cytokine production. We measured TNF-M and IL-Ip in supernatants collected from a standard ADCC assay using each of the anti-colorectal antibodies ml7-lA. c17-1A and cSF25. We found that there was significant TNF-m and IL-lp release during ADCC mediated by each of these three antibodies and that the magntude of cytokine release seemed to reflect the degree of tumour cell Iysis produced by each antibody. Furthermore. se found that effector cells. target cells and a specific anti-tumour antibody A-ere necessarv for this to occur. The presence of only some of the components of the reaction or of an irrelevant antibody produced little or no TNF-m or IL-1p. We conclude that TNF-r and IL-lp are released u-hen an effector and tumour target cell are united by a specific tumour antibody and that these cytokines may be important in bringing about tumour cell lysis during the ADCC reaction.
Monoclonal antibodies directed against tumour-associated antigens bring about tumour cell lysis bv antibody-dependent cell-mediated cytotoxicity (ADCC) (Herlyn et al.. 1979) .
Human peripheral blood monocytes are regarded as important cells involved in tumour regression in viro (Fidler. 1985) and are thought to be important mediators of ADCC (Herlyn et al.. 1979 : Steplewski et al.. 1983 : Adams et al.. 1984 : Johnson et al.. 1986 : Ortaldo et al.. 1987 : Massucci et al.. 1988 : Hellstrom et al.. 1988 . Activated monocytes are known to secrete cytokines such as tumour necrosis factor alpha (TNF-a) (Carswell et al.. 1975 : Haranaka et al.. 1984 : Feinman et al.. 1987 1989) and interleukin 1p (Onozaki et al.. 1985a.b; Okusawa et al.. 1988) and both have been clearly implicated in tumour cytotoxicity. However, very (Ruggerio and Bagglioni. 1987: Smith et al.. 1990) . the aim of this study was to detect the presence of these monocvtederived cy-tokines during the ADCC assay and to establish which if any components of the ADCC assay were necessary for cytokine release. 
ADCC assay
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers and used in an ADCC assay using each of the three antibodies m17-lA. c17-lA and cSF25. The ADCC capacity of peripheral blood mononuclear cells using each of the three anti-colorectal monoclonal antibodies had previously been studied using an 18 h chromium-51 release assay (Pullyblank et al., 1994 Amersham, UK) in 500 ml of phosphate-buffered saline (PBS) for 1 h at 37C. After three washes they were then resuspended in culture medium at a concentration of 2 x 0I cells ml-' and used in the ADCC assay as described above using PBLs from control subjects but in the presence of an anti-TNF-a antibody at a concentration of 2 jig ml-'. Using the ELISA data, the amount of anti-TNF-a antibody used was calculated to be ten times that needed to neutralise the amounts of TNF-a known to be released during the ADCC reaction. Furthermore, preliminary experiments had shown that increasing the amount of blocking antibody above this level of 2 jig ml-' produced no further inhibition of ADCC activity. At the end of the 18 h incubation at 37C, 70 pl aliquots of supernatant were aspirated and counted in a gamma-o counter. The spontaneous release was measured from wells to which culture medium alone was added and the maximum release was measured on wells to which 5% Triton X had been added. The percentage specific lysis was calculated according to the formula: release in sample -spontaneous release Lysis (%o)= x 100 maximum release -spontaneous release Cytotoxicity data were analysed by area under the curve (AUC) of four effector-target ratio points (Dye et al.. 1991 Figure 2 (Pullyblank et al., 1994) show that, of the three anti-tumour antibodies. cSF25 is the most effective mediator of ADCC, with ml7-lA being the least potent. For IL-lp the trend was similar (Figure 3 It seemed, therefore, that target and effector cells needed to be united by an antibody in order to bring about cytokine release. However, in order to test whether this antibody needed to be specific. cytokine levels were measured in supernatants from ADCC assays using both chimeric and murine irrelevant antibodies. For TNF-a, there were no detectable levels of this cytokine in an ADCC assay using the murine antibody RDlI D0 or the chimeric control antibody 7E3.
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Similarly. IL-lp levels were undetectable in supernatants from assays using either the murine control or the chimeric control ( Figure 6 ).
Control experiments
No cytokines were detected in the presence of either of the antibodies alone or in supernatants from PBLs or target cells alone. Likewise, no TNF-a or IL-l p was detected when target cells were incubated with ml7-lA. cl7-lA. cSF25 or either of the control antibodies (Figure 7) 
Inhibition of ADCC using anti-TNF-a antibodies
The results (AUC units ± s.e.m.) show that anti-TNF-a antibody significantly abrogated ml 7-lA-. ci7-lA-and cSF25-mediated killing (Figure 8 ). The presence of anti-TNFa antibody reduced tumour cell lysis from 140 ± 34 to 62 ± 19 for m17-lA, from 257 ± 26 to 209 ± 28 for c17-lA and from 309 ± 18 to 282 ± 21 for cSF25 (P <0.004). Surprisingly. blocking TNF-a activity produced a mean reduction in cytotoxicity of 55% ± 9% with ml7-lA but of only 20% ± 3% with c17-lA and 10% ± 3% with cSF25 despite maximal doses of blocking antibody. This appear to be in contrast to the results of the ELISA, which suggest that more TNF-x is present during ADCC mediated by the chimeric antibodies.
Discussion TNF-a and IL-l0 are known to be released by activated monocytes and are cytotoxic to tumour cells. We have demonstrated that both these cytokines are released during ADCC mediated by the three anti-colorectal antibodies ml7-IA, c17-lA and cSF25. This cytokine release only appears to occur when an effector and target cell are united by a targetspecific monoclonal antibody since little or no TNF-a or IL-lp was detected in the absence of antibody or in the presence of an irrelevant antibody. We have previously examined these anti-colorectal cancer antibodies for their ability to mediate ADCC (Pullyblank et al.. 1994 ). We compared the chimeric antibody. cSF25. which appears to be more tumour specific (Takahashi et al., 1988 (Takahashi et al., . 1989 ) with murine 17-lA (mI7-lA) and chimeric 17-lA (c17-lA), which bind to the 17-lA antigen expressed on both normal colonic mucosa and gastrointestinal adenocarcinomas (Gottlinger et al.. 1986; Sun et al.. 1987) . We found that cSF25 was the most efficient mediator of ADCC and that both the chimenrc antibodies were more effective anti-tumour agents than the murine antibody ml7-lA. The data presented here seem to suggest that more cytokines are released in the presence of antibodies which are more efficient mediators of tumour cell lysis.
This was more apparent for IL-lp release. but the data for TNF-a release showed a similar trend, with a stepwise increase in cytokine release from m17-lA to c17-4A and cSF25 respectively. Since the level of tumour cell lysis seems to parallel that of cytokine release it seems logical to suggest that IL-li and TNF-a may play a role in mediating cytotoxicity during ADCC. In addition, we have previously examined monocyte activation markers in the presence of each of these three antibodies. We found an increase in the expression of the monocyte activation markers, IL-2r and HLA-DR. on monocytes present in the ADCC assay, and this increase was greater in the presence of the antibodies which produced the most tumour cell lysis, again increasing in a stepwise fashion from m17-lA to c17-lA and cSF25. Monocytes have previously been demonstrated to be important mediators of ADCC (Herlyn et al.. 1979; Steplewski et al., 1983 Steplewski et al., . 1986 Adams et al., 1984; Johnson et al., 1986; Ortaldo et al.. 1987; Hellstrom et al., 1988; Massucci et al.. 1988) It has been demonstrated that contact with tumour cells is enough to produce monokine release (Jamncke and Mannel, 1990) . so the presence of specific monoclonal antibodies may merely facilitate this. Close proximity of effector and target cell does seem to be important for cytokine release since, from our data, this seems to be the only situation in which TNF-a and IL-lp were detected. It is impossible to deduce from our results whether linkage via our particular anticolorectal antibodies is important or whether the antibodies purely provide a link allowing close apposition of the cells. Webb et al. (1990) 
